Skip to main content

ULTRALIFE CORP

For the period ended Mar 31, 2026. Filed May 8, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

ULBI$15.66+0.2%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Item 1. Consolidated Financial Statements (unaudited)

Consolidated Balance Sheets as of March 31, 2026 and December 31, 20251
Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the Three-Month Periods Ended March 31, 2026 and March 31, 20252
Consolidated Statements of Cash Flows for the Three-Month Periods Ended March 31, 2026 and March 31, 20253
Consolidated Statements of Changes in Stockholders’ Equity for the Three-Month Periods Ended March 31, 2026 and March 31, 20254
Notes to Consolidated Financial Statements (unaudited)5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16
Item 4.Controls and Procedures23
PART II.OTHER INFORMATION
Item 6.Exhibits25
Signatures26

PART I. FINANCIAL INFORMATION

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In Thousands except share amounts) (Unaudited)

March 31, 2026December 31, 2025
ASSETS
Current assets:
Cash$8,890$9,345
Trade accounts receivable, net of allowance for expected credit losses of $461 and $457, respectively34,42833,948
Inventories, net57,28654,008
Prepaid expenses and other current assets9,4998,500
Total current assets110,103105,801
Property, plant and equipment, net40,11740,397
Goodwill45,32945,376
Other intangible assets, net10,65110,933
Deferred income taxes, net10,76510,494
Other noncurrent assets3,6673,911
Total assets$220,632$216,912
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$24,058$17,423
Current portion of long-term debt3,4384,125
Accrued compensation and related benefits2,8542,754
Accrued expenses and other current liabilities12,70313,031
Total current liabilities43,05337,333
Long-term debt, net44,19045,526
Deferred income taxes9671,000
Other noncurrent liabilities2,6772,919
Total liabilities90,88786,778
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued--
Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 21,092,617 shares at March 31, 2026 and 21,092,617 shares at December 31, 2025; outstanding – 16,656,503 shares at March 31, 2026 and 16,656,503 shares at December 31, 20252,1092,109
Capital in excess of par value192,858192,859
Accumulated deficit(40,791)(40,340)
Accumulated other comprehensive loss(3,058)(3,141)
Treasury stock - at cost; 4,436,114 shares at March 31, 2026 and 4,436,114 shares at December 31, 2025(21,492)(21,492)
Total Ultralife Corporation equity129,626129,995
Non-controlling interest119139
Total stockholders’ equity129,745130,134
Total liabilities and stockholders’ equity$220,632$216,912

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF (LOSS) INCOME AND COMPREHENSIVE (LOSS) INCOME

(In Thousands except per share amounts)

(Unaudited)

Three-month period ended
March 31, 2026March 31, 2025
Revenues$47,445$50,746
Cost of products sold37,33538,001
Gross profit10,11012,745
Operating expenses:
Research and development2,9612,404
Selling, general and administrative7,3646,942
Total operating expenses10,3259,346
Operating (loss) income(215)3,399
Other expense (income):
Interest and financing expense8681,032
Miscellaneous (income) expense(420)(79)
Total other expense448953
(Loss) income before income taxes(663)2,446
Income tax (benefit) provision(192)567
Net (loss) income(471)1,879
Net (loss) income attributable to non-controlling interest(20)14
Net (loss) income attributable to Ultralife Corporation(451)1,865
Other comprehensive (loss) income:
Foreign currency translation adjustments83311
Comprehensive (loss) income attributable to Ultralife Corporation$(368)$2,176
Net (loss) income per share attributable to Ultralife common stockholders – basic$(.03)$.11
Net (loss) income per share attributable to Ultralife common stockholders – diluted$(.03)$.11
Weighted average shares outstanding – basic16,65716,633
Potential common shares-47
Weighted average shares outstanding - diluted16,65716,680

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands) (Unaudited)

Three-month period ended
March 31, 2026March 31, 2025
OPERATING ACTIVITIES:
Net income$(471)$1,879
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation1,054950
Amortization of intangible assets267405
Amortization of financing fees6665
Stock-based compensation(1)227
Deferred income taxes(328)344
Changes in operating assets and liabilities:
Accounts receivable(529)(6,608)
Inventories(3,311)3,614
Prepaid expenses and other assets(740)725
Accounts payable and other liabilities6,2491,767
Net cash provided by operating activities2,2563,368
INVESTING ACTIVITIES:
Purchases of property, plant and equipment(770)(895)
Net cash used in investing activities(770)(895)
FINANCING ACTIVITIES:
Payments on credit facilities(2,063)(687)
Net cash used in financing activities(2,063)(687)
Effect of exchange rate changes on cash12279
(DECREASE) INCREASE IN CASH(455)1,865
Cash, Beginning of period9,3456,854
Cash, End of period$8,890$8,719

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(In thousands except share amounts) (Unaudited)

Capital · Accumulated
Common Stock · in Excess · Other · Non-
Number of · of Par · Comprehensive · Accumulated · Treasury · Controlling
SharesAmountValueIncome (Loss)DeficitStockInterestTotal
Balance – December 31, 202421,069,079$2,107$191,828$(4,006)$(34,442)$(21,492)$192$134,187
Net income1,865141,879
Stock-based compensation – stock options188188
Stock-based compensation - restricted stock3939
Foreign currency translation adjustments311311
Balance – March 31, 202521,069,079$2,107$192,055$(3,695)$(32,577)$(21,492)$206$136,604
Balance – December 31, 202521,092,617$2,109$192,859$(3,141)$(40,340)$(21,492)$139$130,134
Net loss(451)(20)(471)
Stock-based compensation – stock options7878
Stock-based compensation - restricted stock(79)(79)
Foreign currency translation adjustments8383
Balance – March 31, 202621,092,617$2,109$192,858$(3,058)$(40,791)$(21,492)$119$129,745

ULTRALIFE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands except share and per share amounts)

(Unaudited)

1.BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2025.

The December 31, 2025 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.

Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.

Recent Accounting Guidance Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03 “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for the Company’s annual reporting period beginning January 1, 2027, and interim reporting periods beginning January 1, 2028, with early adoption permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its consolidated financial statements.

2.DEBT

On October 31, 2024, Ultralife, SWE, CLB, Excell USA, and Electrochem, as borrowers, and certain other subsidiaries of the Company, entered into a new Credit and Security Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent (the “New Credit Agreement”). The proceeds of the loans under the New Credit Agreement were used, in part, to repay outstanding indebtedness under the Company’s then existing Credit and Security Agreement with KeyBank (the “Amended Credit Agreement”).

The New Credit Agreement, among other things, provides in its term loan provisions for a 5-year, $55 million senior secured term loan (the “Term Loan” or “Term Loan Facility”). The Term Loan is subject to repayment in quarterly installments commencing March 31, 2025, in amounts as set forth in the New Credit Agreement. Interest is payable on the unpaid principal outstanding under the Term Loan. All amounts of unpaid principal and accrued and unpaid interest remaining due under the Term Loan are scheduled to be paid in full October 31, 2029.

Upon closing of the acquisition of all issued and outstanding shares of Electrochem on October 31, 2024, the Company borrowed the full amount of the Term Loan Facility.

As of March 31, 2026, the Company had $48,188 outstanding principal on the Term Loan, $3,438 of which is included in current portion of long-term debt on the consolidated balance sheets, andno amounts outstanding on the Revolving Credit Facility. As of March 31, 2026, unamortized debt issuance costs associated with the Term Loan of $560 are classified on the consolidated balance sheets as a reduction of long-term debt, and unamortized debt issuance costs associated with the Revolving Credit Facility of $387 are classified on the consolidated balance sheets as other noncurrent assets. Debt issuance costs include lender fees and certain costs paid to third parties, including legal and accountant fees, and are amortized to interest expense over the term of the New Credit Agreement.

The New Credit Agreement also provides under its revolving credit provisions for revolving loans, letters of credit, and swing loans (“Revolving Credit Facility”). Upon the effectiveness of the New Credit Agreement, any amounts outstanding under letters of credit issued pursuant to the Amended Credit Agreement became issued under the New Credit Agreement. The availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on October 31, 2029.

The Company may voluntarily prepay principal amounts outstanding under the New Credit Agreement at any time subject to certain advance notifications and other restrictions.

In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated fixed charge coverage ratio, as defined in the New Credit Agreement, of equal to or greater than 1.15 to 1.00 for the fiscal quarter ending March 31, 2025, and for each fiscal quarter thereafter, as calculated for the four (4) consecutive fiscal quarters ending on such date, and a consolidated senior leverage ratio, as defined in the New Credit Agreement, not to exceed (i)3.50 to 1.00 for the fiscal quarters ending March 31, 2025 through December 31, 2025, (ii)3.25 to 1.00 for the fiscal quarters ending March 31, 2026 through December 31, 2026, (iii)3.00 to 1.00 for the fiscal quarter ending March 31, 2027 and on the last day of each fiscal quarter thereafter, for the remaining term of the New Credit Agreement. The Company was in full compliance with its covenants under the New Credit Agreement as of March 31, 2026.

Borrowings under the New Credit Agreement are secured by substantially all the assets of the Company and certain of its present and future subsidiaries who are or become parties to, or guarantors under the New Credit Agreement.

Interest will accrue on outstanding indebtedness under the Term Loan Facility and Revolving Credit Facilities at a variable rate of interest based on designated interest rate benchmarks plus a varying margin determined by reference to the consolidated senior leverage ratio in effect from time to time. Our borrowing rate was 6.13% as of March 31, 2026.

The Company must pay a fee of twenty, twenty-five or thirty basis points (depending on the consolidated senior leverage ratio in effect from time to time) based on the average daily unused availability under the Revolving Credit Facility.

The Company must make payments to the extent borrowings exceed the maximum amount then permitted to be borrowed and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.

Future minimum principal repayment obligations on our Amended Credit Facilities as of March 31, 2026 are as follows:

2026$2,063
20275,500
20285,500
202935,125
Total$48,188
3.EARNINGS PER SHARE

Basic earnings (loss) per share (“EPS”) is computed by dividing net (loss) income attributable to Ultralife by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities when the average market price exceeds the exercise price of the securities, if any, and is calculated using the treasury stock method.

For the three-month period ended March 31, 2026, there wereno outstanding equity awards included in the calculation of diluted weighted average shares outstanding, and no potential common shares included in the calculation of diluted EPS, as no securities were dilutive. There were 963,482 outstanding stock options and 19,943 unvested restricted stock awards not included in the calculation of EPS for the three-month period ended March 31, 2026, as the effect would be anti-dilutive.

For the comparable three-month period ended March 31, 2025, there were 314,704 outstanding stock options included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 46,793 potential common shares included in the calculation of diluted EPS. There were 778,717 outstanding stock options and 35,486 unvested restricted stock awards for the three-month period ended March 31, 2025, not included in the calculation of diluted weighted average shares outstanding, as the effect would be anti-dilutive.

4.SUPPLEMENTAL BALANCE SHEET INFORMATION

Fair Value Measurements and Disclosures

The fair value of financial instruments approximated their carrying values at March 31, 2026, and December 31, 2025. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments. The carrying value of long-term debt approximates fair value, as the variable interest rates approximate current market rates.

Inventories, Net

Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:

March 31,December 31,
20262025
Raw materials$44,720$42,150
Work in process5,9664,045
Finished goods6,6007,813
Total$57,286$54,008

Property, Plant and Equipment, Net

Major classes of property, plant and equipment consisted of the following:

March 31,December 31,
20262025
Land$4,693$4,693
Buildings and leasehold improvements30,38230,179
Machinery and equipment64,24263,556
Furniture and fixtures3,2153,195
Computer hardware and software8,5958,164
Construction in process2,6273,129
113,754112,916
Less: Accumulated depreciation(73,637)(72,519)
Property, plant and equipment, net$40,117$40,397

Depreciation expense for property, plant and equipment was as follows:

Three-month period ended
March 31,March 31,
20262025
Depreciation expense$1,054$950

Goodwill

The following table summarizes the goodwill activity by segment for the three-month period ended March 31, 2026.

Battery & Energy · Communications
ProductsSystemsTotal
Balance – December 31, 2025$33,883$11,493$45,376
Effect of foreign currency translation(47)-(47)
Balance – March 31, 2026$33,836$11,493$45,329

Other Intangible Assets, Net

The composition of other intangible assets was:

Accumulated
CostAmortizationNet
Customer relationships$18,286$8,567$9,719
Patents and technology5,7435,625118
Other1,500686814
Total other intangible assets$25,529$14,878$10,651
Accumulated
CostAmortizationNet
Customer relationships$18,333$8,360$9,973
Patents and technology5,7625,635127
Other1,500667833
Total other intangible assets$25,595$14,662$10,933

The change in the cost of total intangible assets from December 31, 2025, to March 31, 2026, is the effect of foreign currency translations.

Amortization expense for other intangible assets was as follows:

Three-month period ended
March 31,March 31,
20262025
Amortization included in:
Selling, general and administrative$262$376
Research and development529
Total amortization expense$267$405
5.STOCK-BASED COMPENSATION

We recorded non-cash stock compensation expense in each period as follows:

Three-month period ended
March 31,March 31,
20262025
Stock options$78$188
Restricted stock(79)39
Total$(1)$227

We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of March 31, 2026, there was $308 of total unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted average period of 1.1 years.

The following table summarizes stock option activity for the three-month period ended March 31, 2026:

Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (years)Aggregate Intrinsic Value
Outstanding at January 1, 2026967,351$6.95
Granted5,000$5.92
Exercised--
Forfeited or expired(8,869)$6.58
Outstanding at March 31, 2026963,482$6.953.60$250
Vested and expected to vest at March 31, 2026908,569$6.923.49$249
Exercisable at March 31, 2026735,301$6.773.02$247

Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended March 31, 2026, and 2025 was $0, respectively.

Restricted stock awards vest in equal annual installments over three (3) years. Unrecognized compensation cost related to unvested restricted shares at March 31, 2026, and 2025, respectively, was $75 and $216.

6.INCOME TAXES

Our effective tax rate for the three-month periods ended March 31, 2026 and 2025 was 29.0% and 23.2%, respectively. The period-over-period change was primarily attributable to the geographic mix of our operating results and other income recognized on nontaxable refundable tax credits under the 45X Advanced Manufacturing Production Credit.

On July 4, 2025, the One Big Beautiful Bill Act was signed into law in the United States which includes a broad range of tax provisions affecting businesses. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The Company has included the estimated impacts of the bill in the consolidated financial statements for the three-month period ended March 31, 2026.

As of December 31, 2025, our federal net operating loss (“NOL”) carryforwards, state net operating loss carryforwards, and federal general business tax credit carryforwards were $8,800, $5,100 and $3,400, respectively. Our domestic net operating loss carryforwards begin to expire in 2031. Our federal general business tax credit carryforwards begin to expire in 2028. As of March 31, 2026, management has concluded it is more likely than not that these domestic NOL and credit carryforwards will be fully utilized.

As of March 31, 2026, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $10,000, nearly all of which can be carried forward indefinitely. Utilization of the net operating losses may be limited due to the change in the past U.K. operation and cannot currently be used to reduce taxable income at our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.

As of March 31, 2026, we havenot recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.

As of March 31, 2026, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.

There wereno unrecognized tax benefits related to uncertain tax positions at March 31, 2026 and December 31, 2025.

As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2022 thru 2024 remain subject to IRS examination. Our U.S. tax matters for 2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2015 thru 2024 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2015 thru 2024 remain subject to examination by the respective foreign tax jurisdiction authorities.

7.OPERATING LEASES

The Company has operating leases predominantly for operating facilities. As of March 31, 2026, the remaining lease terms on our operating leases range from approximately one (1) year to six (6) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.

The components of lease expense for the current and prior-year comparative periods were as follows:

Three-months ended
March 31, 2026March 31, 2025
Operating lease cost$456$296
Variable lease cost2124
Total lease cost$477$320

Supplemental cash flow information related to leases was as follows:

Three-month period ended March 31,
2026 · 2025
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$272$314
Right-of-use assets obtained in exchange for lease liabilities:$-$-

Supplemental consolidated balance sheet information related to leases was as follows:

Balance sheet classification · March 31, 2026 · December 31, 2025
Assets:
Operating lease right-of-use assetOther noncurrent assets$3,121$3,344
Liabilities:
Current operating lease liabilityAccrued expenses and other current liabilities$927$976
Operating lease liability, net of current portionOther noncurrent liabilities2,1782,357
Total operating lease liability$3,105$3,333
Weighted-average remaining lease term (years)3.94.1
Weighted-average discount rate7.1%7.1%

Future minimum lease payments as of March 31, 2026, are as follows:

Maturity of operating lease liabilities
2026$729
2027946
2028935
2029580
2030154
Thereafter192
Total lease payments3,536
Less: Imputed interest(431)
Present value of remaining lease payments$3,105
8.COMMITMENTS AND CONTINGENCIES

Purchase Commitments

As of March 31, 2026, we have made commitments to purchase approximately $545 of production machinery and equipment.

Product Warranties

We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first three months of 2026 and 2025 were as follows:

Three-month period ended March 31,
20262025
Accrued warranty obligations – beginning$1,126$887
Accruals for warranties issued4993
Settlements made(9)(6)
Accrued warranty obligations – ending$1,166$974

Contingencies and Legal Matters

We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.

9.REVENUE RECOGNITION

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheets. For the three-month periods ended March 31, 2026 and March 31, 2025, revenue recognized on extended warranties was $74.

As of March 31, 2026, there was deferred revenue on extended warranty contracts of $781, comprised of $298 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheets, and $483 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheets.

As of December 31, 2025, there was deferred revenue on extended warranty contracts of $855, comprised of $298 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheets, and $557 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheets.

As of March 31, 2026, and December 31, 2025, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

10.BUSINESS SEGMENT INFORMATION

Operating segments represent a component of the Company that engages in business activities from which it may recognize revenues and incur expenses whose operating results are regularly reviewed by the public entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. Upon identification of operating segments, the Company determines which of those operating segments are required to be presented as reportable segments based on the quantitative thresholds.

We structure our operations primarily around the products we sell and report our financial results in the followingtwo reportable segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design.

Our CODM is Mike Manna, President & Chief Executive Officer. Both of our operating segments are regularly reviewed by the CODM through weekly revenue, gross margin and consolidated financial forecast updates, bi-weekly business and financial reviews to assess business performance, top priorities, utilization of resources and to regularly communicate with segment management, who are part of the CODM’s executive leadership team, and monthly meetings with the executive leadership team. In his role as CODM, Mr. Manna is deeply involved in business operations through daily updates by the segment management and ongoing financial, revenue and operations discussions.

The primary financial measures used by the CODM to monitor and evaluate the performance of the operating segments is segment contribution, as defined by gross profit less direct selling, general and administrative (“SG&A”) and research and development expenses. This metric is used as a consistent benchmark for comparison across reporting periods.

The significant segment expenses regularly reviewed by the CODM and included in segment contribution are cost of products sold and direct R&D and SG&A expenses. There are no other segment items included in segment contribution beyond the significant expenses disclosed.

Corporate general and administrative (“G&A”) expenses, including costs associated with our acquisitions, include corporate functions including board of directors, executive officers, accounting & finance, human resources, legal, information technology and their related functional expenses. These costs are not directly allocable to the operating segments.

The CODM does not review segment assets at a level other than that presented in the Company’s consolidated balance sheets.

Three-month period ended March 31, 2026:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$44,155$3,290$-$47,445
Cost of products sold(34,797)(2,538)-(37,335)
Gross profit9,358752-10,110
Direct SG&A expenses(4,081)(379)-(4,460)
Research and development(2,222)(739)-(2,961)
Segment contribution3,055(366)-2,689
Corporate G&A expenses(2,904)(2,904)
Operating loss(215)
Other expenses, net(448)(448)
Income tax (benefit)(192)(192)
Non-controlling interest(20)(20)
Net loss attributable to Ultralife$(451)
Total assets$169,847$27,322$23,463$220,632
Depreciation and amortization of intangible assets$1,222$57$42$1,321

Three-month period ended March 31, 2025:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$46,321$4,425$-$50,746
Cost of products sold(34,881)(3,120)-(38,001)
Gross profit11,4401,305-12,745
Direct SG&A expenses(3,865)(366)-(4,231)
Research and development(1,591)(813)-(2,404)
Segment contribution5,984126-6,110
Corporate G&A expenses(2,711)(2,711)
Operating income3,399
Other expenses, net(953)(953)
Income tax provision567567
Non-controlling interest1414
Net income attributable to Ultralife$1,865
Total assets$173,169$30,006$20,578$223,753
Depreciation and amortization of intangible assets$1,265$58$33$1,356

The following tables disaggregate our business segment revenues by major source and geography.

Commercial and Government/Defense Revenue Information:

Three-month period ended March 31, 2026:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$44,155$30,505$13,650
Communications Systems3,290-3,290
Total$47,445$30,505$16,940
64%36%

Three-month period ended March 31, 2025:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$46,321$32,287$14,034
Communications Systems4,425-4,425
Total$50,746$32,287$18,459
64%36%

U.S. and Non-U.S. Revenue Information 1:

Three-month period ended March 31, 2026:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$44,155$28,943$15,212
Communications Systems3,2902,307983
Total$47,445$31,250$16,195
66%34%

Three-month period ended March 31, 2025:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$46,321$35,182$11,139
Communications Systems4,4254,287138
Total$50,746$39,469$11,277
78%22%

1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.